ArticleJournal of gastroenterology2026
An interpretable machine learning model for predicting survival in pancreatic cancer via SHAP: a multicenter study.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable machine learning prediction of 1-year overall survival in pancreatic cancer patients aged 65 years and older.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundExisting pancreatic cancer prediction models still have significant limitations until now. This multicenter retrospective study aimed to identify clinical features and develop machine learning models for predicting overall survival (OS) in patients with pancreatic cancer.
methodsClinicopathological and survival data from patients with pancreatic cancer who underwent radical surgery between 2012 and 2023 were collected at two major pancreatic centers in China. A total of 704 patients from the National Cancer Center of China (NCC) formed the training and internal validation cohort, while 131 patients from Sun Yat-sen Memorial Hospital constituted the external validation cohort. Five predictive machine learning models were developed and validated, and the optimal predictive model was determined by comparing area under the receiver operating characteristic curve (AUC) values. The SHapley Additive exPlanation (SHAP) method was employed to provide interpretability for the machine learning model.
resultsThe median OS for 704 postoperative pancreatic cancer patients in NCC was 24 months (21-26 months), with 1-year, 3-year, and 5-year survival rates of 72.8%, 34.0%, and 22.1%, respectively. Perioperative chemotherapy was significantly associated with improved survival (P = 0.0026). Survival data for NCC were generally consistent with Japan and the United States. Among the five predictive models, the Random Survival Forest (RSF) model exhibited superior performance, achieving AUC values of 0.81, 0.76 and 0.78 in the training, internal and external validation sets. The most influential variables contributing to the model predictions were identified using the SHAP method, with those of particular importance including chemotherapy, CA19-9, abdominal pain, the number of lymph node resection and TNM stage.
conclusionsThe 5-year survival rate for postoperative pancreatic cancer patients is 22.1% in NCC, which is comparable with the United States and Japan. Based on multicenter clinical data, we developed and validated an interpretable survival prediction model, which can guide clinical management and personalized treatment for pancreatic cancer patients.
Indexed as
Identifiers
41615460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.